Dutch Norgine BV will take-over Merus Labs International Inc. Under the agreement, Norgine will acquire all outstanding shares for US$1.65 per share in cash.
A study conducted by an NIH institute proves Roches Avastin is as effective as Regenerons Eylea, a drug that costs 30 times more than Roches antibody. The rub: Avastin is not approved for use in central retinal vein occlusion (CRVO).
https://european-biotechnology.com/wp-content/uploads/2024/04/Eylea_NEI.jpg8141157Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-05-11 10:23:012017-05-11 10:23:01Cheap Avastin as effective as Eylea in CRVO
Fiasco in Phase III: Roches conditionally approved PD-L1 checkpoint inhibitor did not meet the endpoint of overall survival vs chemotherapy in a confirmatory study with pre-treated patients with metastatic urothelial cancer.
https://european-biotechnology.com/wp-content/uploads/2024/04/Roche_PD_L1.png315680Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-05-10 08:01:072017-05-10 08:01:07Roches anti-PD-L1 fails in bladder cancer
GMO world market adoption is further growing. GMO cultivation area in 2016 increased to 185.1 million hectares versus 2015 (179.7m hectares), 3% up globally, and from 116,870 in 2015 to 136,363 hectares, 17% up, in the EU.
With an impressive 11.7% growth in sales compared with 2015, the Swiss biotech sector has grown more strongly in 2016 than the years before. However, after three years of growth, Swiss biotech companies collected almost CHF100m less than in the previous year, according to the most recent Swiss Biotech Report.
https://european-biotechnology.com/wp-content/uploads/2024/04/2017_05_05_sbd17.jpg6301120Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-05-05 14:27:162017-05-05 14:27:16Another great year for Swiss biotech
The Biotechnology in Germany is a growth engine. According to a new report, all key figures such as employees, turnover and R&D expenditure were at an all-time high in 2016.
https://european-biotechnology.com/wp-content/uploads/2024/04/German_Biotechnology_Sector_2017.jpeg450800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-05-04 14:32:322017-05-04 14:32:32German biotech on the rise
The french biotechnology company Vivet Therapeutics has raised €37.5 million in a Series A financing round. Amongst others, Novartis Venture Fund and Roche Venture Fund were involved.
https://european-biotechnology.com/wp-content/uploads/2024/04/2017_05_04_Money_Euro.png6301120Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-05-04 13:57:342017-05-04 13:57:34€37.5 million for Vivet Therapeutics
The Boehringer Ingelheim Venture Fund leads a financing consortium that collected €20m for French cancer therapy developer Imcheck. The Marseille-based company also presented its new CEO.
https://european-biotechnology.com/wp-content/uploads/2024/04/2017_05_03_marseille.jpg6301120Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-05-03 14:11:352017-05-03 14:11:35Boehringer leads Series A of French Imcheck
German Adrenomed AG has decided to start clinical Phase II tests of the very first personalised treatment for the six million patients with acute congestive heart failure. Large trials suggest that the company can stratify patients resistant to diuretics standard therapy by a proprietary companion diagnostics blood test. Adrenomed will assess whether its first-in-class antibody adrecizumab can reverse the congestion that that manifests as pulmonary edema.
Norgine to acquire Merus
Latest NewsDutch Norgine BV will take-over Merus Labs International Inc. Under the agreement, Norgine will acquire all outstanding shares for US$1.65 per share in cash.
Cheap Avastin as effective as Eylea in CRVO
Latest NewsA study conducted by an NIH institute proves Roches Avastin is as effective as Regenerons Eylea, a drug that costs 30 times more than Roches antibody. The rub: Avastin is not approved for use in central retinal vein occlusion (CRVO).
Roches anti-PD-L1 fails in bladder cancer
Latest NewsFiasco in Phase III: Roches conditionally approved PD-L1 checkpoint inhibitor did not meet the endpoint of overall survival vs chemotherapy in a confirmatory study with pre-treated patients with metastatic urothelial cancer.
Dermtreat bags €16.2m financing
Latest NewsMucosal inflammation specialist Dermtreat ApS (Copenhagen) has secured a Series A financing worth €16.2m (US$17.7m).
GMO acreage growing
Latest NewsGMO world market adoption is further growing. GMO cultivation area in 2016 increased to 185.1 million hectares versus 2015 (179.7m hectares), 3% up globally, and from 116,870 in 2015 to 136,363 hectares, 17% up, in the EU.
Another great year for Swiss biotech
Latest NewsWith an impressive 11.7% growth in sales compared with 2015, the Swiss biotech sector has grown more strongly in 2016 than the years before. However, after three years of growth, Swiss biotech companies collected almost CHF100m less than in the previous year, according to the most recent Swiss Biotech Report.
German biotech on the rise
Latest NewsThe Biotechnology in Germany is a growth engine. According to a new report, all key figures such as employees, turnover and R&D expenditure were at an all-time high in 2016.
€37.5 million for Vivet Therapeutics
Latest NewsThe french biotechnology company Vivet Therapeutics has raised €37.5 million in a Series A financing round. Amongst others, Novartis Venture Fund and Roche Venture Fund were involved.
Boehringer leads Series A of French Imcheck
Latest NewsThe Boehringer Ingelheim Venture Fund leads a financing consortium that collected €20m for French cancer therapy developer Imcheck. The Marseille-based company also presented its new CEO.
Preventing congestion in acute heart failure patients
Background